logo

Crowdly

Browser

Add to Chrome

BMS3031 - Molecular mechanisms of disease - S1 2026

Looking for BMS3031 - Molecular mechanisms of disease - S1 2026 test answers and solutions? Browse our comprehensive collection of verified answers for BMS3031 - Molecular mechanisms of disease - S1 2026 at learning.monash.edu.

Get instant access to accurate answers and detailed explanations for your course questions. Our community-driven platform helps students succeed!

A clinician is considering antibiotic therapy for a patient

with a

Mycobacterium

infection. Vancomycin is highly effective against

many Gram-positive bacteria, but it is generally ineffective against

Mycobacteria, which is Gram-positive.

Which explanation best accounts for the intrinsic resistance

of Mycobacteria to vancomycin?

View this question

Genetic analyses suggest SARS‑CoV‑2 originated from bat

coronaviruses with possible adaptation in intermediate mammalian hosts.

Replication in these hosts allows viral evolution toward efficient interaction

with mammalian ACE2‑like receptors, without eliminating the virus’s ability to circulate in reservoir species.

Over time, what consequence does this process most strongly

promote?

View this question

Genomic surveillance shows that SARS‑CoV‑2

continues to accumulate mutations during global circulation. Many mutations

affect the spike protein, particularly regions involved in immune recognition,

while genes involved in core replication remain highly conserved. Variants with

altered antigenic profiles repeatedly emerge and replace earlier strains.

Given prolonged global circulation in humans,

what long‑term pattern is most likely?

View this question

The Omicron variant of SARS‑CoV‑2 exhibited a much higher basic

reproductive number (R₀) than earlier variants. Consider a future variant with

a similarly high R₀ that causes very mild or subclinical infection in most

individuals. Infected individuals frequently continue normal activities while

infectious.

Across multiple epidemic waves, what population‑level

consequence is most likely?

View this question

Following widespread vaccination and natural infection, much

of the human population has partial immunity to SARS‑CoV‑2.

A new variant arises that is less effectively neutralised by existing

antibodies, while retaining strong ACE2 binding and efficient transmission. The

variant shows no increased virulence or replication cost.

If introduced into such a population, what outcome is most

likely over time?

0%
0%
0%
View this question

SARS‑CoV‑2 has a lower case fatality rate

than SARS or MERS, yet caused far greater global spread. Consider a

hypothetical SARS‑CoV‑2 variant that increases disease

severity modestly but causes earlier hospitalisation and reduces the duration

of infectiousness in the community. Viral replication within the host remains

unchanged.

Over successive transmission cycles, what impact would this

most likely have on pandemic spread?

View this question

Coronaviruses frequently circulate in bat reservoirs,

occasionally spilling over into humans where most infections fail to establish

sustained transmission. A novel coronavirus spill-over event produces a virus

capable of infecting human airway cells, but initially spreads inefficiently

between people. Subsequent mutations improve human receptor binding and viral

shedding without reducing replication in animal reservoirs or humans.

Given sufficient opportunity for adaptation and global

population movement, what outcome best explains how such a virus could become

pandemic?

View this question

Early analyses of COVID‑19 case numbers showed that viral

spread strongly correlated with population movement from initial outbreak

regions. Imagine a SARS‑CoV‑2–like

virus emerges, but rapid international travel restrictions and large‑scale

movement controls are implemented before widespread dissemination occurs. The

virus retains the same biological transmissibility.

Given these conditions, what outcome is most likely over

time?

View this question

Reassortment between avian and human influenza viruses

generates a new subtype with a haemagglutinin to which humans lack immunity.

The new virus transmits efficiently with no intrinsic fitness cost.

What is the most likely long‑term consequence following introduction

into humans?

View this question

SARS‑CoV‑2 enters human cells by binding

the ACE2 receptor via its spike protein. Genomic surveillance identifies a new

viral variant carrying multiple spike mutations that significantly increase

binding affinity to human ACE2. Laboratory studies show enhanced cell entry and

higher transmission rates in animal and human airway models. Importantly, this

variant shows no reduction in viral stability, replication efficiency, or

disease severity compared to earlier strains.

Assuming sustained human‑to‑human transmission and no

immediate population‑level immunity shift, what outcome is most likely over

time?

View this question

Want instant access to all verified answers on learning.monash.edu?

Get Unlimited Answers To Exam Questions - Install Crowdly Extension Now!

Browser

Add to Chrome